Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan

Sanada, Takahiro; Honda, Tomoko; Higa, Masahiko; Yamaji, Kenzaburo; Yasui, Fumihiko; Kohara, Michinori

doi:10.1016/j.jiac.2022.12.012

Cited by 4 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After waning of S-antibody levels, further booster doses increase S-antibody levels again. We observed a marked increase in GMC shortly following the first booster compared to the primary series and a further increase after the second booster dose in line with previous findings (5, 11, 19-22). However, the increase in GMC shortly following the second booster compared to the first booster was much smaller.…”

Section: Discussionsupporting

confidence: 92%

“…In line with our results, lower S-antibody levels shortly after vaccination among those of higher age or with medical conditions have been reported for the primary series (2-5, 15, 16). Also, Sanada et al reported that the effect of age was no longer present following the first booster dose (11). We observed that S-antibody levels were still lower in the older age group shortly after the first booster dose.…”

Section: Discussionsupporting

confidence: 41%

“…Also, Sanada et al . reported that the effect of age was no longer present following the first booster dose (11). We observed that S-antibody levels were still lower in the older age group shortly after the first booster dose.…”

Section: Discussionmentioning

confidence: 99%

“…Booster doses have been reported to produce higher antibody concentrations than after the previous dose (5, 11). Age-dependent antibody responses have been reported after the primary series, with younger persons reaching higher levels (2, 5, 11). In the study by Wei et al, this effect was also observed after the first booster (5).…”

Section: Introductionmentioning

confidence: 99%

“…In the study by Wei et al, this effect was also observed after the first booster (5). However, differences between age groups have been reported to become smaller with increasing number of doses (2, 11). In the Netherlands, people with asplenia, diabetes, cardiovascular disease, immune disorder, cancer with current or no treatment, lung disease or asthma, hepatic disease, neurological disease, renal disease, organ or bonemarrow transplantation were prioritized for the primary series and booster vaccinations.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study

Hoeve,

Huiberts,

de Gier

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Information on the magnitude and duration of antibody levels after COVID-19 vaccination in different groups may be useful for prioritizing of additional vaccinations. Methods Serum samples were collected every six months in a prospective cohort study among adults in the Netherlands. Geometric mean concentrations (GMCs) of antibodies against the receptor binding domain of the SARS-CoV-2 spike protein were calculated after the primary series, first, and second booster vaccinations. Effects of age (18-59 vs 60-85 years) and medical risk conditions on GMC 2-6 weeks and 21-25 weeks after each vaccination, and on waning during 3-25 weeks after each vaccination, were estimated by linear regression. Results We included 20,816, 16,820 and 5,879 samples collected after primary, first and second booster vaccination, respectively. GMCs at 2-6 and 21-25 weeks after primary series were lower in participants with older age or medical risk conditions. After the first booster, older age was associated with lower GMC at 2-6 weeks, higher GMC at 21-25 weeks, and slower waning. GMCs or waning after the first and second boosters (only 60-85) were not associated with medical risk conditions. Conclusions Since antibody differences by age and medical risk groups have become small with increasing number of doses, other factors such as disease severity rather than antibody levels are useful for prioritization of additional vaccinations.

show abstract